JP7850068B2 - 高親油性生理活性物質の放出制御製剤 - Google Patents

高親油性生理活性物質の放出制御製剤

Info

Publication number
JP7850068B2
JP7850068B2 JP2022521680A JP2022521680A JP7850068B2 JP 7850068 B2 JP7850068 B2 JP 7850068B2 JP 2022521680 A JP2022521680 A JP 2022521680A JP 2022521680 A JP2022521680 A JP 2022521680A JP 7850068 B2 JP7850068 B2 JP 7850068B2
Authority
JP
Japan
Prior art keywords
product according
weight
highly lipophilic
core
cannabinoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022521680A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553652A (ja
JP2022553652A5 (https=
JPWO2021074399A5 (https=
Inventor
ノヴァク，ミルコ
ジェスコ ノヴァク，ジェイ
グラーヴェ，アネット
ヴェンツラフ，モニカ
バルトルト，サラ
ゴイゲリン，クリスティアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADD Advanced Drug Delivery Technologies AG
Original Assignee
ADD Advanced Drug Delivery Technologies AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADD Advanced Drug Delivery Technologies AG filed Critical ADD Advanced Drug Delivery Technologies AG
Publication of JP2022553652A publication Critical patent/JP2022553652A/ja
Publication of JP2022553652A5 publication Critical patent/JP2022553652A5/ja
Publication of JPWO2021074399A5 publication Critical patent/JPWO2021074399A5/ja
Priority to JP2025279962A priority Critical patent/JP2026034780A/ja
Application granted granted Critical
Publication of JP7850068B2 publication Critical patent/JP7850068B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022521680A 2019-10-16 2020-10-16 高親油性生理活性物質の放出制御製剤 Active JP7850068B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025279962A JP2026034780A (ja) 2019-10-16 2025-12-24 高親油性生理活性物質の放出制御製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19203549.1A EP3808336A1 (de) 2019-10-16 2019-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
EP19203549.1 2019-10-16
PCT/EP2020/079244 WO2021074399A1 (de) 2019-10-16 2020-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025279962A Division JP2026034780A (ja) 2019-10-16 2025-12-24 高親油性生理活性物質の放出制御製剤

Publications (4)

Publication Number Publication Date
JP2022553652A JP2022553652A (ja) 2022-12-26
JP2022553652A5 JP2022553652A5 (https=) 2023-10-19
JPWO2021074399A5 JPWO2021074399A5 (https=) 2023-10-19
JP7850068B2 true JP7850068B2 (ja) 2026-04-22

Family

ID=68281165

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521680A Active JP7850068B2 (ja) 2019-10-16 2020-10-16 高親油性生理活性物質の放出制御製剤
JP2025279962A Pending JP2026034780A (ja) 2019-10-16 2025-12-24 高親油性生理活性物質の放出制御製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025279962A Pending JP2026034780A (ja) 2019-10-16 2025-12-24 高親油性生理活性物質の放出制御製剤

Country Status (10)

Country Link
US (1) US20240148758A1 (https=)
EP (2) EP3808336A1 (https=)
JP (2) JP7850068B2 (https=)
CN (1) CN114929197A (https=)
AU (1) AU2020366134B2 (https=)
BR (1) BR112022006678A2 (https=)
CA (1) CA3157693A1 (https=)
IL (1) IL292019A (https=)
MX (1) MX2022004522A (https=)
WO (1) WO2021074399A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048045A1 (en) 2010-10-05 2012-04-12 Jb Therapeutics, Inc. Compositions, dosages, and methods of using tetrahydrocannabinol derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
SK287111B6 (sk) * 1998-08-27 2009-12-07 Pharmacia & Upjohn Ab Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
AU2014340709B2 (en) 2013-10-29 2019-07-04 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
WO2018035030A1 (en) 2016-08-15 2018-02-22 Corr-Jensen Inc. Time release fat-soluble actives
EP3808341A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048045A1 (en) 2010-10-05 2012-04-12 Jb Therapeutics, Inc. Compositions, dosages, and methods of using tetrahydrocannabinol derivatives

Also Published As

Publication number Publication date
JP2022553652A (ja) 2022-12-26
CN114929197A (zh) 2022-08-19
JP2026034780A (ja) 2026-02-27
AU2020366134A1 (en) 2022-05-26
MX2022004522A (es) 2022-09-19
IL292019A (en) 2022-06-01
CA3157693A1 (en) 2021-04-22
US20240148758A1 (en) 2024-05-09
EP4045007A1 (de) 2022-08-24
EP3808336A1 (de) 2021-04-21
AU2020366134B2 (en) 2026-04-23
WO2021074399A1 (de) 2021-04-22
BR112022006678A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
JP2025182116A (ja) 高親油性生理活性物質の放出制御製剤
CA3162353A1 (en) Oral cannabinoid formulations
WO2021228365A1 (en) Uses and formulations of cannabinoids
AU2022349666B2 (en) Cannabinoid formulation for oral administration
JP7850068B2 (ja) 高親油性生理活性物質の放出制御製剤
JP2024514171A (ja) カンナビノイドの製剤
EP4074307B1 (en) Formulations of cannabinoids
CN117715626A (zh) 大麻素的制剂
TR201612582A1 (tr) Oral farmasöti̇k terki̇pler
TR201612581A1 (tr) Oral farmasöti̇k terki̇pler

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260410